Abstract:78 Background: The rising incidence of early-onset colorectal cancer (CRC) has prompted U.S. organizations to lower the recommended CRC screening age for average risk adults from 50 to 45 years old, while Canadian programs remain unchanged. Canadian guidelines also differ from the U.S. in preferentially screening with a fecal immunochemical test (FIT) and recommending against colonoscopies as a screening test. Differences in national healthcare administration warrants investigation into the resource impact of updating screening guidance in Canada. Methods: Microsimulation modeling was performed using OncoSim (version 3.6) to project health and economic outcomes of different CRC screening strategies based on Canadian population data. Four simulated birth cohorts of the Canadian population born between 1973–1992 were tracked for a 40-year span from the year the oldest in each cohort turned 40 until the youngest in the same cohort turned 75. Colorectal adenoma rates were adjusted according to cohort risk ratios estimated from historical incidence data to reflect real-world CRC rates. Outcomes were reported for the cumulative cohort. Results: Compared to FIT screening at age 50, FIT screening at 45 reduced deaths by 5,220, incidence by 11,980, and added 96,100 health-adjusted life years (HALY). Colonoscopy screening at age 45 led to 17,870 fewer deaths, 74,250 fewer cases and added 314,960 HALYs. FIT and colonoscopy screening at age 45 had incremental costs of CAD$3,259 and $7,881 per HALY gained vs. a FIT at age 50, respectively. Across screening strategies, the greatest benefits were observed in the youngest cohort. Colonoscopy screening at age 45 resulted in 10,679,540 more total colonoscopies than the current capacity of 8,966,979 with FIT screening at age 50. Lowering the screening age to 45 with a FIT increased colonoscopy demand by 329,555. The total cost of CRC care (screening, diagnosis and treatment) increased with lower screening ages and colonoscopy first modalities, while the cost of CRC management (diagnosis and treatment) decreased with lower screening ages and colonoscopy first approaches. Conclusions: Adjusting current CRC screening guidelines demonstrates significant resource implications with proportional health benefits. Lower screening ages and colonoscopy first approaches have the largest resource demand and greatest health outcomes, while the incremental cost per HALY gained for all screening strategies is modest compared to standard benchmarks. [Table: see text]

The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society …

Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline

[Influence of Age on Advanced Neoplasia Detection in Colorectal Cancer Screening in Population at High Risk].

Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model

Population-level impact of the BMJ Rapid Recommendation for colorectal cancer screening: a microsimulation analysis

Should colorectal cancer screening start at different ages for men and women? Cost-effectiveness analysis for a resource-constrained service

Impact of revising colorectal cancer screening guidelines on health care resources in Canada.

Optimal timing of a colonoscopy screening schedule depends on adenoma detection, adenoma risk, adherence to screening and the screening objective: A microsimulation study

Colorectal cancer screening test exposure patterns in US adults 45 to 49 years of age, 2019-2021

Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis

Cost-utility of colorectal cancer screening at 40 years old for average-risk patients

Cost-Effectiveness of Earlier or More Intensive Colorectal Cancer Screening in Overweight and Obese Patients

Colorectal cancer screening from 45 years of age: Thesis, antithesis and synthesis

S401 Colorectal Cancer Screening in 45-49 and 50-54-Year-Olds Detects Similar Rates of High-Risk Findings: Results From a U.S.-Wide Cloud-Based Data Set

The impact of multi-target stool DNA testing in clinical practice in the United States: A real-world evidence retrospective study

The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population

Commencing colorectal cancer screening at age 45 years in U.S. racial groups

Changing colon cancer screening guidelines to age 45: Has it made a difference?

Colorectal Cancer Screening Based on Age and Gender: A Cost-Effectiveness Analysis.

Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study